Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling
- 1 April 2006
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 17 (4) , 429-438
- https://doi.org/10.1097/01.cad.0000203388.68034.06
Abstract
PCK3145 is a synthetic peptide corresponding to amino acids 31–45 of prostate secretory protein 94 which can reduce experimental skeletal metastases and prostate tumor growth. These anti-metastatic and anti-tumoral effects of PCK3145 are partially explained by the in-vivo and in-vitro decrease in matrix metalloproteinase (MMP)-9 extracellular levels through as yet unidentified molecular mechanisms of action. Gelatin zymography and immunoblots were used to monitor the levels of secreted MMP-9 from HT-1080 cells. Flow cytometry was used to monitor HT-1080 cell surface binding of FITC-labeled PCK3145 and biotin-labeled laminin. PCK3145-coated cell culture dishes were used to monitor cell adhesion. HT-1080 cell lysates were used for immunoblotting of HuR, extracellular signal-regulated protein kinase (ERK) and phospho-ERK. Total RNA was isolated and RT-PCR used to monitor HuR gene expression. We found that PCK3145 bound to the HT-1080 cell surface and that this binding rapidly triggered ERK phosphorylation that, ultimately, led to a reduction of secreted MMP-9. Laminin inhibited both cell surface binding and ERK phosphorylation by PCK3145. Overexpression of the 67-kDa laminin receptor led to an increased binding of the cells to PCK3145. HuR, a protein that can bind to and stabilize MMP-9 mRNA, was found to be downregulated by PCK3145. The mitogen-activated protein kinase/ERK (MEK) inhibitor PD98059 as well as native laminin and SIKVAV laminin-derived peptide prevented that downregulation. Our data suggest that PCK3145 rapidly triggers intracellular signaling through cell surface laminin receptors. This leads to decreased HuR expression and subsequent destabilization of MMP-9 transcripts. This is the first molecular evidence demonstrating the intracellular signaling and anti-metastatic mechanism of action of PCK3145 that leads to the inhibition of MMP-9 secretion.Keywords
This publication has 22 references indexed in Scilit:
- Three predominant prostatic proteins: Drei vorherrschende ProstataproteineAndrologia, 2009
- A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor MetastasisClinical & Experimental Metastasis, 2005
- Laminin-induced signaling in tumor cellsCancer Letters, 2004
- A Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein Can Reduce Tumor Growth, Experimental Skeletal Metastases, and Malignancy-Associated HypercalcemiaCancer Research, 2004
- Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell lineOral Oncology, 2004
- ATP Potentiates Interleukin-1β-induced MMP-9 Expression in Mesangial Cells via Recruitment of the ELAV Protein HuRJournal of Biological Chemistry, 2003
- Matrix Metalloproteinases and Their Inhibitors in Human Pituitary TumorsNeurosurgery, 1999
- DETECTION OF PSP94 AND ITS SPECIFIC BINDING SITES IN THE PROSTATE ADENOCARCINOMA CELL LINE LNCaPJournal of Urology, 1998
- Cloning and Characterization of HuR, a Ubiquitously Expressed Elav-like ProteinJournal of Biological Chemistry, 1996
- Studies of binding and internalization of human recombinant monocyte chemotactic and activating factor (MCAF) by monocytic cellsCytokine, 1993